Trial Profile
To Evaluate the Efficacy and Safety of Nilotinib Treatment on Subclinical Cardiovascular Biomakers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2015
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 31 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.